A trial of ranitidine in asthmatic children and adolescents with or without pathological gastro-oesophageal reflux.
In order to study the importance of gastro-oesophageal reflux (GOR) as a trigger of asthma the effect of inhibition of gastric acid secretion on asthma was assessed in a double-blind, cross-over, placebo-controlled trial over four weeks in 37 children and adolescents (mean age 14 yrs) with bronchial asthma. Ranitidine 300 mg, (150 mg if B.W. was less than 40 kg) was given as a single evening dose during four weeks. In previous investigations 18 of the 37 patients had been shown to have pathological GOR by 24 h pH monitoring in the oesophagus. The remaining 19 patients with normal GOR served as controls for possible effects of ranitidine on asthma, not related to reduction of GOR. A modest (30%) but statistically significant reduction of nocturnal asthma symptoms was produced by ranitidine in the patients with pathological GOR when compared to those with normal GOR. There was a significant correlation between the improvement in asthma symptoms and the degree of acid reflux. Side-effects of ranitidine were negligible. Acid reflux appears to be only a weak stimulus for bronchoconstriction in children and adolescents with bronchial asthma and pathological GOR. Further confirmative trials with more potent inhibitors of gastric acid secretion are, however, warranted.
Gustafsson
P M
PM
Dept of Paediatrics, Faculty of Health Sciences, University Hospital, Linköping, Sweden.
Kjellman
N I
NI
Tibbling
L
L
D000293:Adolescent; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D002648:Child; D002940:Circadian Rhythm; D004311:Double-Blind Method; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D011899:Ranitidine / Q000627:therapeutic use*; D015656:Respiratory Mechanics; D011795:Surveys and Questionnaires
D011899:Ranitidine